Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe

Shaum A.; Mujuru H.A.; Takamiya M.Ticklay I.Nathoo K.Sreenivasan N.Nyambayo P.Chitando P.Marembo J.Koline Chigodo C.Mukaratirwa A.Jacha V.Gidudu J.F.Rupfutse M.Kumar Jain S.Manangazira P.Bennett S.D.

首页> 外文期刊>Vaccine >Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe

【24h】

Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe

机译：Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

© 2022Background: During February 25–March 4, 2019, Zimbabwe's Ministry of Health and Child Care conducted an emergency campaign using 342,000 doses of typhoid conjugate vaccine (TCV) targeting individuals 6 months–15 years of age in eight high-risk suburbs of Harare and up to 45 years of age in one suburb of Harare. The campaign represented the first use of TCV in Africa outside of clinical trials. Methods: Three methods were used to capture adverse events during the campaign and for 42 days following the last dose administered: (1) active surveillance in two Harare hospitals, (2) national passive surveillance, and (3) a post-campaign coverage survey. Results: Thirty-nine adverse events were identified during active surveillance, including 19 seizure cases (16 were febrile), 16 hypersensitivity cases, 1 thrombocytopenia case, 1 anaphylaxis case, and two cases with two conditions. Only 21 (54%) of 39 patients were hospitalized and 38 recovered without sequelae. Attack rates per 100,000 TCV doses administered were highest for seizures (6.27) and hypersensitivity (5.02). Only 6 adverse events were reported through passive surveillance by facilities other than the two active surveillance hospitals. A total of 177 (10%) of 1,817 vaccinees surveyed reported experiencing an adverse event during the post-campaign coverage survey, of which 25 (14%) sought care. Conclusions: In line with previous evaluations of TCV, enhanced adverse event monitoring during an emergency campaign supports the safety of TCV. The majority of reported events were minor or resulted in recovery without long-term sequelae. Attack rates for seizures and hypersensitivity were low compared with previous active surveillance studies conducted in Kenya and Burkina Faso. Strengthening adverse event monitoring in Zimbabwe and establishing background rates of conditions of interest in the general population may improve future safety monitoring during new vaccine introductions.

著录项

来源
《Vaccine》 |2022年第26期|3573-3580|共8页
作者
Shaum A.; Mujuru H.A.; Takamiya M.Ticklay I.Nathoo K.Sreenivasan N.Nyambayo P.Chitando P.Marembo J.Koline Chigodo C.Mukaratirwa A.Jacha V.Gidudu J.F.Rupfutse M.Kumar Jain S.Manangazira P.Bennett S.D.;
展开▼
作者单位

National Foundation for the Centers for Disease Control and Prevention;

Centers for Disease Control and Prevention;

UZ Faculty of Medicine and Health SciencesSally Mugabe HospitalParirenyatwa HospitalMedicine Control Authority of ZimbabweCity of Harare Health DepartmentMinistry of Health and Child CareWorld Health Organization;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类医学免疫学;
关键词
Active surveillance; Adverse events following immunization; Typhoid outbreak; Typhoid vaccine; Vaccine campaign; Vaccine safety;

Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe

摘要

著录项

相关主题

期刊订阅